Please see full Prescribing Information, including Boxed WARNING and Medication Guide at the “Learn more” link above or here: bit.ly/FABHPI.
FABHALTA is a Novartis Pharmaceuticals Corporation product and is not associated with any individual users on LinkedIn. This information is for US health care professionals only.
To report suspected adverse reactions, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
FABHALTA and the FABHALTA logo are registered trademarks of Novartis AG.
This page is sponsored by Novartis Pharmaceuticals Corporation.
7/24 FA-11221016
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.fabhalta-hcp.com
Fabhalta® (Iptacopan) Hcp Questions
Fabhalta® (Iptacopan) Hcp's website is https://www.fabhalta-hcp.com
Fabhalta® (Iptacopan) Hcp's LinkedIn profile is https://www.linkedin.com/company/fabhalta-hcp
Fabhalta® (Iptacopan) Hcp's industry is
Pharmaceutical Manufacturing
Fabhalta® (Iptacopan) Hcp's top competitors are
Doptelet® (Avatrombopag) Hcp,
Novartis,
Amgen,
Zerbaxa® (Ceftolozane And Tazobactam) Hcp,
Krystexxa® (Pegloticase) Hcp,
Lexicon Pharmaceuticals, Inc.,
Kisqali Hcp,
Scemblix® (Asciminib) Tablets Hcp,
Empaveli® (Pegcetacoplan) Hcp,
Cimzia® (Certolizumab Pegol) Hcp.
Fabhalta® (Iptacopan) Hcp's categories are Pharmaceutical Manufacturing
